Purpose-Nuclear Hypoxia-Inducible Factor 1 Alpha (HIF1a) is involved in tumor response to microenvironmental stress and may initiate development of micrometastases and chemoradiation resistance. The goal of this analysis was to evaluate HIF1a expression as a prognostic factor for distant recurrence (DR) and local recurrence (LR) following pancreatic adenocarcinoma (PAC) resection.
INTRODUCTION
Pancreatic adenocarcinoma (PAC) remains the fourth leading cause of cancer death in the United States today and carries an extremely poor prognosis, with 5-year survival rates remaining near 5%. Out of the estimated 44,000 newly diagnosed cases of pancreatic cancer in 2012, 37,400 deaths are expected. 1 Although incremental gains have been made in treatment strategies, complete resection remains the only hope for cure. Methods for stratifying patients and tailoring treatment for pancreatic adenocarcinoma rely mainly on descriptive clinicopathologic features such as TNM stage, margin status, perineural invasion and CA19-9, all of which have modest prognostic value. One accepted treatment algorithm after pancreatic resection is to administer adjuvant chemoradiation. 2, 3 Even with curative resection, five-year survival rates remain around 20%. At least 40% of patients have metastatic disease at presentation, and another 30-40% have locally advanced disease not lending itself to curative intent resection. Several potential molecular biomarkers have been studied in pancreatic cancer with varying degrees of clinical utility.
HIF-1α, which in turn causes tumor cells to experience an adaptive switch to angiogenic signaling, glycolytic metabolism, and subsequent micrometastases. This ability to respond to microenvironmental stress may lead in turn to tumor resistance to available thereapeutic approaches. High levels of HIF-1α activity likely increase tumor growth, vascularization and glucose metabolism and also reflect more clinically aggressive tumors due to an association with p53 mutations. HIF-1α expression has been suggested as a clinical marker of aggressive disease, poor prognosis and treatment resistance in other cancers, such as ovarian tumors 5 , cervical cancer 6 and more recently in other gastrointestinal malignancies such as esophageal and colorectal cancer 7 , potentially through regulation of hypoxia-based tumorstromal interactions. 8 The aim of this study was to evaluate the role of HIF-1α expression in prognosticating survival and patterns of failure in patients with resectable PAC.
MATERIALS AND METHODS

Patient Selection
Ninety-eight patients were selected for this analysis, based on availability of pancreatic cancer resection specimens. These patients presented with early-stage PAC and underwent pancreaticoduodenectomy with curative intent between January of 2000 and January of 2011 at XXX Hospital. Patients who received neoadjuvant chemotherapy or radiation were excluded to avoid bias in biomarker interpretation. Approximately 30 of these patients were included in previous reports by the authors. 9-11 Overall survival and followup time were calculated using date of surgery as the initial contact. Chart review was conducted to obtain patient demographics, treatment characteristics and pathologic characteristics. Patients were followed for five years or until date of death. Local recurrence was defined as either recurrent disease in the pancreas, pancreatic bed or associated nodal regions. Distant recurrence was defined as radiologic or pathologically confirmed recurrent disease in other sites. Documented recurrence required either biopsy confirmed disease consistent with pancreatic primary or progressive disease on two consecutive post-treatment surveillance scans at any time point. Permission was obtained from the Institutional Review Board and patient confidentiality was maintained according to the Health Insurance and Patient Accessibility Act of 1996.
Immunohistochemical Analysis
This institution has a well defined tissue banking protocol in which representative fresh samples from the tumor are stored immediately after gross sectioning, often less than one hour after the specimen is resected, in order to minimize protein degradation. In order to prevent effects of intraoperative procedures, including electrocautery, representative tumor samples were chosen for the study away from tumor periphery. Representative sections of tumor were selected using formalin-fixed paraffin embedded slides reviewed by two expert pancreatic pathologists (NA, BS). Due to intratumoral heterogeneity, tissue microarray (TMA) blocks were created in quadruplicate using 5mm diameter punches from carefully selected cellular foci of tumor. The TMA cores were reviewed for homogeneity. TMA cores were stained for nuclear HIF-1α expression using anti-HIF-1α monoclonal mouse antibody (NB100-105, Novus Biologicals, Littleton, CO) under optimized staining conditions at a dilution of 1:400 using positive and negative control tissues according to manufacturer recommendations. Due to heterogeneity of HIF-1α expression, all four TMA cores were reviewed for each sample. Nuclear expression levels of HIF-1α were determined by an experienced pancreatic pathologist (SB) blinded to patient outcomes and clinical data with an additional pancreatic pathologist available for review (NA). Immunohistochemical (IHC) expression scores were calculated based on a previously defined scoring system incorporating intensity and percent of cells staining. 10-13 Intensity of cells staining was recorded as follows: 0 = no staining, 1= weak staining, 2=moderate staining, 3=strong staining. Percentage of staining was recorded as follows: 0 = less than 1% of cells staining positive, 1= 1-10% of cells staining positive, 2 = 11-49% of cells staining positive, 3= 50-80% of cells staining positive, 4= greater than 80% of cells staining positive. A combined score was then calculated using the following equation: Score = ((1+ intensity)/3) X percent. This combined score equation allows for the percentage of cells staining to carry greater weight as it is thought to be more biologically relevant.
In addition to analysis of the calculated scores as a continuous variable, scores were divided into low and high expression levels. High expression level tumors were required to exhibit both high staining intensity (2-3) and high percentage of cells staining (>50%), and thus had a calculated score >1.33, while low expression level tumors exhibited low staining intensity (0-1) and low percentage of cells staining (<=50%) and thus had a calculated score ≤1.33.
Statistical Analysis
Descriptive characteristics were generated for all clinicopathologic covariates, patient demographics, clinical outcomes and biomarker intensity, percent and score. Median and interquartile ranges were generated for continuous variables and frequency statistics were generated for categorical variables. Descriptive characteristics were generated for the endpoints of recurrence pattern, death or loss to follow-up for all patients.
Patient characteristics were summarized and compared between patients with high or low HIF-1α expression using ANOVA (analysis of variance) or Wilcoxon rank-sum test for numerical covariates and chi-square test or Fisher's exact test for categorical covariates where appropriate. Univariate association of HIF-1α expression with covariates was assessed using Wilcoxon rank-sum test or Kruskal-Wallis test for categorical covariates, where appropriate; and Spearman correlation for numerical covariates. Covariates included HIF-1α percentage, intensity and expression score, age, sex, ethnicity, receipt of adjuvant chemotherapy and/or radiation, tumor size, margin status, nodal status, grade, perineural invasion (PNI), and lymphovascular invasion (LVI). In order to eliminate death as a competing endpoint for recurrence and to directly compare isolated LR to DR, a subgroup analysis was performed including only patients with known recurrence before death or patients alive with disease. This excluded patients with no documented recurrence due to loss to follow-up or whose death was due to non-cancer causes. Univariate and Multivariable analysis of LR and DR were conducted using a logistic regression model. The best predictive model of LR and DR was identified using a backward variable selection method with an alpha level of removal set at 0.1. HIF-1α was forced in the multivariable model. Receiver operating characteristic (ROC) curves and predictive probability curves were generated for biomarker expression as a predictor of LR and DR. All analyses were done 
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RESULTS
Overall Characteristics
Median followup time was 16.3 months (range 0.85 -61.6 months) and median survival time was 30.6 months (range 12.1-49.1 months). Median recurrence-free survival time was 9.05 months (range 0.85 -61.6 months). Median age was 67.8 years (range 36-88 years). The patient population was 69.7% (n=62) Caucasian and 21.4% (n=27) African-American. At resection, median tumor maximum diameter was 3.5 cm (range 10-70 cm), 70% (n=71) patients were lymph node positive and 26.8% (n=26) patients had positive margins. Nuclear HIF-1α demonstrated differential expression among samples ( figure 1 ). Median HIF-1α expression score was 2 (range 0-5.33) and mean score was 1.81 (SD ± 1.28). 85% (n=80) of patients received adjuvant chemotherapy and 20% (n=17) of patients received adjuvant radiotherapy. The remainder of the patient demographics and clinicopathologic characteristics are summarized in Table 1 .
The only factors associated with high HIF-1α expression level on univariate analysis (table  2a, table 2b ) were pattern of failure (p=.035) and age (p=.010).
Patterns of Failure
In all patients with recurrence, HIF-1α expression score was significantly associated with distant recurrence versus isolated local recurrence (p=.028, figure 2a ). Both receiver operating characteristic curve (figure 2b) for HIF-1α score as a predictor of distant recurrence and predicted probability curve (figure 2c) demonstrate high specificity for distant recurrence with high HIF-1α score in all patients with recurrence. The percentage of each failure type by HIF-1α score ( figure 2d) demonstrates the local recurrence group, which is composed primarily of low HIF-1α scores, the distant/local recurrence group, which is composed of a broad range of scores, and the distant recurrence group, which is composed of predominantly high scores.
On univariate analysis, low HIF-1α expression was significantly related to LR (OR 0. 
DISCUSSION
In this study, high nuclear HIF-1α expression was highly specific as a predictive biomarker for distant recurrence of disease. Many biomarkers have been studied in pancreatic cancer, including other biomarkers involved in angiogenesis, tumor growth and invasion, and chemotherapy metabolism. 14, 15 Few of these markers have been linked to specific patterns of failure in pancreatic cancer, as this study has demonstrated. The loss of one such biomarker, SMAD4, was associated with increased pattern of distant failure in patients with advanced pancreatic cancer in a rapid autopsy series, 16 but this association did not stand in patients with earlier stage resectable pancreatic cancer, 17 potentially due to less aggressive tumor biology or earlier disease in these patients. This makes nuclear HIF-1α, to our knowledge, one of the first biomarkers to identify specific patterns of failure in early-stage pancreatic cancer patients.
Previous small studies have associated nuclear HIF-1α expression with lymph node metastases and decreased disease-free survival, 18 although data on overall survival has been inconsistent. [18] [19] [20] Nuclear HIF-1α has also been associated with both metastatic disease in other tumor types 5, 6, 21, 22 and with aggressive tumor histology in cell line and tissue studies of pancreatic cancer. 4, 19, 23 Although cytoplasmic HIF-1α is expressed in both non-tumor and tumor pancreatic tissue, nuclear HIF-1α is expressed in approximately 88% of pancreatic ductal carcinomas versus only 16% of normal pancreas tissues, and is expressed by adjacent stroma to tumor in 43% cases, which suggests a role of HIF-1α in metastatic tumor behavior. [24] [25] [26] Nuclear HIF-1α appears to be more specific to tumor tissue 26 and the value of analyzing stromal expression remains under investigation. 8 Recent studies have suggested a potential link between tumor hypoxia and HIF-1α activated stromal proliferation that may promote metastatic behavior; this link deserves further evaluation. 8 It has been unclear whether nuclear HIF-1α expression levels are a result of treatment response by tumors or a marker of aggressive tumor behavior, thus this study analyzed only tissue samples from patients that had not been previously exposed to chemotherapy or radiation therapy. This inclusion criterion may contribute to the excellent median overall survival of this patient cohort, despite standard of care adjuvant treatment and good median follow up; this selection bias should be noted but does not preclude the useful interpretation of this data. The lower than expected recurrence rate may be attributed to strict requirements for documentation of recurrence in this retrospective analysis.
A pancreatic cancer biomarker that is predictive of failure patterns may be very timely as the role of radiation therapy versus isolated adjuvant chemotherapy in resected pancreatic cancer remains under debate. Several large studies have shown an advantage to adjuvant chemotherapy alone over adjuvant chemoradiation 27 yet 30% of PAC patients still die from locally aggressive disease rather than widespread metastatic disease. 16 Modern and advancing radiation therapy techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), allow the administration of larger radiation doses with sparing of surrounding structures and can provide excellent local control in selected patients. 28 Identifying those patients with resected PAC who are likely to develop isolated local or distant metastatic disease may have two-fold clinical benefit: prognostic information may help select patients for local radiation therapy and/or more aggressive systemic chemotherapy, and the development of targeted agents may prevent distant metastases and thus increase the effectiveness of local therapies and improve survival. With further investigation, it is also possible that this information could help stratify patients with resectable and borderline resectable tumors who would benefit from neoadjuvant therapy.
This data also justifies the further development of potential therapeutic targets, including HIF-1α inhibitors 29 and HSP90 inhibitors as both systemic agents and as radiosensitizing agents. When radiation is administered to a hypoxic tumor, the radiation dose must be nearly tripled in order to achieve comparable cell killing as compared to oxygenated tissue, which also increases normal tissue toxicity. Pancreatic adenocarcinoma is among the most hypoxic of all solid tumors, and HIF-1α inhibitors have been investigated pre-clinically as one method of increasing radiation response by decreasing resistance to radiation-induced apoptosis. 24, 25 HIF-1α expression has also been associated with gemcitabine resistance in hypoxic environments, indicating HIF-1α may have a role in potentiating systemic therapeutic agents. 30 Unfortunately, prognostic and predictive biomarker studies are fraught with issues of transparency and reproducibility. The Guidelines for the Reporting of Tumor MARKer Studies (REMARK) were developed and published in 2005 to provide a framework of study design and completeness of reporting for studies of prognostic biomarkers. [31] [32] [33] [34] [35] [36] [37] [38] Although this retrospective study focuses on a predictive biomarker, the guidelines remain relevant and every effort was made to accurately report all 20 elements of the REMARK criteria. Similarly, the biological relevance of cut point determination in IHC studies, including HIF-1α, remains unclear, and thus biomarker studies remain prone to inaccurate conclusions due to arbitrary cut point delineation or determining cut points based on the produced data. Expression data was analyzed using continuous variables in addition to dichotomized expression levels, which minimizes this ambiguity; however, for the purposes of practical clinical utility, a pre-determined and standardized dichotomized system is necessary. The use of a uniform "scoring system" incorporating both intensity of staining and percentage of cells staining and standardized cut point determination allows better representation of overall expression and should be adopted and maintained in further prospective studies. The use of a quality controlled tissue banking protocol also will help minimize the interval between resection and fixation and susceptibility to fixation conditions of HIF-1α.
This study suggests that nuclear HIF-1α expression level at time of resection for early-stage PAC is a predictor of eventual distant failure versus local failure. While this analysis provides important hypothesis-generating data supported by previous studies of HIF-1α expression in PAC, future studies are necessary to validate these findings and to prospectively evaluate the role of HIF-1α expression in a larger, more homogeneous patient cohort, such as evaluation as a secondary endpoint in a future cooperative group trial. Distribution of Wilcoxon scores for HIF1a score by site of recurrence (2a) demonstrates statistically significant difference between mean HIF1a score for isolated locoregional versus distant recurrence. Both Receiver operating characteristic curve (2b) for HIF1a score as a predictor of distant recurrence and predicted probability curve (2c) demonstrate high specificity for distant recurrence with high HIF1a score in all patients with recurrence. The percentage of each failure type by HIF1a score (2d), with darkest shading representing lowest scores and lightest shading representing higher scores, demonstrates the local recurrence group composed primarily of low HIF1a scores, distant/local recurrence group composed of a broad range of scores and the distant recurrence group composed of predominantly high scores. Small numbers above figure 2b represent predicted probabilities. Table 3 Univariate analysis of Isolated Local Recurrence F1All patients without missing data were included in fitted model; see Table 1 for missing data.
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